Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 3/20 | 0.50 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28923852 | 1.00 | BDKRB2 (0.50) | BDKRB2NMUR2NMUR1NTSR1GRB2 | |
| SCHEMBL29377971 | 0.93 | F2 (0.55) | BDKRB2NTSR1GRB2F2OPRD1 | |
| SCHEMBL29364295 | 0.90 | BDKRB2 (0.48) | BDKRB2NTSR1GRB2F2 | |
| SCHEMBL2317887 | 0.89 | CXCR4 (0.48) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL2317896 | 0.89 | CXCR4 (0.48) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL28923776 | 0.89 | CXCR4 (0.48) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL29495157 | 0.86 | CXCR4 (0.51) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL30080797 | 0.86 | OPRM1 (0.51) | NMUR2NMUR1NTSR1GRB2F2 | |
| SCHEMBL29582550 | 0.85 | BDKRB2 (0.48) | BDKRB2NMUR2NTSR1F2 | |
| SCHEMBL29886085 | 0.85 | EPHA2 (0.49) | NMUR2NMUR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095077-A | Polyvinylpyrrolidone-based hydrogels for 3D cell culture | — | 2026-05-26 | — | — | CN | claimed |
| EP-4709837-A1 | LYMPHOID TISSUES WITH SWITCHABLE PROTEIN GRADIENTS | Georgia Tech Research Corporation (US) | 2026-03-18 | — | — | EP | claimed |
| US-20250339581-A1 | SYNTHETIC HYDROGEL CARRIERS FOR MUSCLE REPAIR | GEORGIA TECH RES INST (US) | 2025-11-06 | — | — | US | claimed |
| US-20250325978-A1 | PHOTOPATTERNED HYDROGELS | GEORGIA TECH RES INST (US) | 2025-10-23 | — | — | US | claimed |
| US-12397084-B2 | Synthetic hydrogel carriers for muscle repair | GEORGIA TECH RESEARCH CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| US-20250136927-A1 | COMPOSITION FOR 3D TISSUE CULTURE | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2025-05-01 | — | — | US | claimed |
| WO-2025090290-A1 | POLYVINYLPYRROLIDINE-BASED HYDROGELS FOR 3D CELL CULTURE | CORNING INCORPORATED (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2025080462-A1 | CHITOSAN-BASED HYDROGELS FOR 3D CELL CULTURE | CORNING INCORPORATED (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4531947-A1 | PHOTOPATTERNED HYDROGELS | Georgia Tech Research Corporation (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2024233793-A1 | LYMPHOID TISSUES WITH SWITCHABLE PROTEIN GRADIENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2023235850-A1 | PHOTOPATTERNED HYDROGELS | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-12-07 | — | — | WO | claimed |
| US-11718687-B2 | Biomoletron for regulation stem cell differentiation | SOGANGN UNIVERSITY RESEARCH FOUNDATION (KR) | 2023-08-08 | — | — | US | claimed |
| CN-115054737-B | Endothelialization-promoting nickel-titanium alloy vascular stent surface coating and preparation method thereof | 中国科学院金属研究所 | 2023-06-06 | — | — | CN | claimed |
| CN-111848658-B | Mitochondria-targeted fluoroborodipyrrole compound, preparation method and application of liposome-coated nano particles thereof | 浙江理工大学 | 2023-05-05 | — | — | CN | claimed |
| WO-2023041529-A1 | COMPOSITION FOR 3D TISSUE CULTURE | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2023-03-23 | — | — | WO | claimed |
| US-11565024-B2 | Lysostaphin containing synthetic hydrogel carriers for bone repair | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-01-31 | — | — | US | claimed |
| WO-2022232592-A1 | CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-11-03 | — | — | WO | claimed |
| US-11478571-B2 | Synthetic hydrogel carriers for cellular structures, generation of organoids, and treatment of tissue injury | GEORGIA TECH RESEARCH CORPORATION (US) | 2022-10-25 | — | — | US | claimed |
| CN-115054737-A | Nickel-titanium alloy intravascular stent surface coating for promoting endothelialization and preparation method thereof | 中国科学院金属研究所 | 2022-09-16 | — | — | CN | claimed |
| CN-111135298-B | Amphiphilic BODIPY compound and preparation method and application thereof | 浙江理工大学 | 2022-07-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478571-B2 | Synthetic hydrogel carriers for cellular structures, generation of organoids, and treatment of tissue injury | KRT18, ILK, CNN2 | BDKRB2 1726/4885NMUR2 1301/4885NMUR1 1425/4885 |
| US-20250325978-A1 | PHOTOPATTERNED HYDROGELS | HPGDS, CD44, RAD54L | BDKRB2 2985/4885NMUR2 1149/4885NMUR1 1383/4885 |
| US-11565024-B2 | Lysostaphin containing synthetic hydrogel carriers for bone repair | PLOD3, BMP2, ILK | BDKRB2 2381/4885NMUR2 1456/4885NMUR1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.